Product category:
Chromatographs: gas
News Release from: Agilent Technologies Europe
Edited by the Laboratorytalk Editorial
Team on 28 August 2006
Calando selects Agilent for siRNA
production
Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research, has selected Agilent Technologies to manufacture the active siRNA component in its lead RNAi product, Calaa01
Calando was formed in 2005 to create, develop and commercialize proprietary technologies for the therapeutic use of RNA interference, or RNAi Calaa01 is the first targeted siRNA anti-cancer therapeutic that Calando plans to enter into Phase I clinical trials
This article was originally published on Laboratorytalk on 30 Jun 2008 at 8.00am (UK)
Related stories
Agilent updates CGH microarray software
For large-scale experiments, Agilent DNA Analytics 4.0 can process more than 100 microarrays (244K), helping users easily compare data and visualise patterns
Agilent upgrades EZChrom Elite for China and Japan
The software is now localised into Chinese and Japanese, features a single walk-up sample entry screen and offers updated workstation compliance
Agilent will provide the siRNA component of Calaa01 for Investigational New Drug (IND)- enabling pharmacokinetic and toxicity studies as well as cGMP production for the Phase I clinical study.
"Establishing the manufacturing relationship with Agilent for CALAA01 is a major milestone in our development timeline," said Calando CEO John Petrovich.
"We are very impressed with the depth of experience and strong leadership the Agilent team has to offer.
"In addition, we appreciated the team's ability to offer a complete package of development services, including development of analytical methods, IND supporting studies and stability.
"These attributes are vitally important in the manufacture of therapeutics as complex as siRNA duplexes".
"We're very pleased to be selected by Calando to provide manufacturing and IND-enabling services for their lead RNAi product," said James Powell, general manager of Agilent's nucleic acid solutions division.
"Calando is one of the leading RNAi therapeutics companies, due to their focus on development and commercialization of targeted siRNA therapeutics based on proprietary technologies, and we look forward to working closely with them.".
• Agilent Technologies Europe: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
